A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

Inclusion Criteria:

• Best corrected visual acuity in the study eye between 20/30 and light perception (LP)

• Willingness to provide signed informed consent and Health Insurance Portability andAccountability Act (HIPAA) authorization

• Age ≥ 18 years

• For sexually active women of childbearing potential, agreement to the use of anappropriate form of contraception (or abstinence) for the duration of the study

Exclusion Criteria:

• History of anti-VEGF treatment in the study eye

• History of previous pars plana vitrectomy in the study eye

• Intraocular surgery in the study eye within one month of the study

• Patients with extensive vitreous hemorrhage in conjunction with a rhegmatogenousretinal detachment

• Tractional retinal detachment from causes inconsistent with PDR, such as inflammationor trauma

• Any concurrent intraocular condition in the study eye that could either requiremedical or surgical intervention during the study period to prevent or treat visualloss that might result from that condition or if allowed to progress untreated couldlikely contribute to loss of at least 2 Snellen equivalent lines of BCVA over thestudy period.

• Active intraocular inflammation (grade trace or above) in the study eye

• Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in eithereye

• Uncontrolled glaucoma in the study eye (defined as IOP≥ 35 mmHg despite treatment withanti-glaucoma medication)

• History of glaucoma-filtering surgery in the study eye

• History of corneal transplant in the study eye